Sangui Biotech Return On Asset vs. Current Valuation
| SGBI Stock | USD 0 0.00 0.00% |
For Sangui Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sangui Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sangui Biotech International utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sangui Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sangui Biotech International over time as well as its relative position and ranking within its peers.
Sangui |
Sangui Biotech Inter Current Valuation vs. Return On Asset Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Sangui Biotech's current stock value. Our valuation model uses many indicators to compare Sangui Biotech value to that of its competitors to determine the firm's financial worth. Sangui Biotech International is currently regarded as top stock in return on asset category among its peers. It also is currently regarded number one company in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Sangui Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Sangui Biotech's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Sangui Current Valuation vs. Return On Asset
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Sangui Biotech |
| = | -0.64 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Sangui Biotech |
| = | 1.68 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Sangui Current Valuation vs Competition
Sangui Biotech International is currently regarded number one company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Drug Manufacturers—Specialty & Generic industry is at this time estimated at about 5.55 Billion. Sangui Biotech adds roughly 1.68 Million in current valuation claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.
Sangui Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Sangui Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sangui Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Sangui Biotech's change in net profit over the period of time. It can combine multiple indicators of Sangui Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany. Sangui Biotech is traded on OTC Exchange in the United States.
Sangui Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Sangui Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sangui Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sangui Biotech's important profitability drivers and their relationship over time.
Use Sangui Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sangui Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sangui Biotech will appreciate offsetting losses from the drop in the long position's value.Sangui Biotech Pair Trading
Sangui Biotech International Pair Trading Analysis
The ability to find closely correlated positions to Sangui Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sangui Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sangui Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sangui Biotech International to buy it.
The correlation of Sangui Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sangui Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sangui Biotech Inter moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sangui Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Sangui Biotech position
In addition to having Sangui Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Funds Thematic Idea Now
Aggressive Funds
Funds or Etfs that attempt to achieve high capital gains by investing in companies with high growth potential and above average risk. The Aggressive Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Sangui Pink Sheet
To fully project Sangui Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sangui Biotech Inter at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sangui Biotech's income statement, its balance sheet, and the statement of cash flows.